Bioactive Peptides and Derivatives as Therapeutic Agents: Potential Applications in Disease Treatment
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 125
Special Issue Editor
Interests: bioactive peptide; adrenomedullin; inflammatory bowel disease; COVID-19; hypertension
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Bioactive peptides help to maintain equilibrium in organisms, and their imbalance is closely related to the development of pathological conditions. Relative or absolute deficiencies in bioactive peptides are observed in many diseases, and thus, their replenishment can improve disease outcomes. Historically, insulin is a bioactive peptide, and many derivatives of native insulin are currently used as therapeutic agents in diabetic patients. Peptide analogs of glucagon-like peptide (GLP-1) have been developed for the treatment of diabetes, and GLP-1 also shows benefit in the treatment of obesity and cardiovascular diseases and is currently being explored for Parkinson’s disease. The applications of bioactive peptides can be diverse and varied. Adrenomedullin and its related peptides were initially developed by many researchers, including our group, as therapeutic agents for cardiovascular diseases due to their strong vasodilative activity. However, their use in therapeutic indications is expanding further to inflammatory diseases such as inflammatory bowel disease and other conditions including sepsis, pneumonia, and COVID-19.
In this Special Issue, we cordially invite authors and investigators to submit original research or review articles pertaining to the use of bioactive peptides and derivatives, particularly their progressive applications and innovative possibilities as therapeutic agents for various diseases.
Dr. Toshihiro Kita
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- bioactive peptide
- peptide modification
- application
- cardiovascular disease
- inflammatory disease
- digestive disease
- neurological disease
- drug development
